The higher-dosage GLP-1 agonists largely engendered greater cardiometabolic improvements.
GLP-1 drugs could become personalized for individuals, study says
Trending
- The ‘1K-yard, 10-TD catch seasons’ quiz
- Rank Your Dating Priorities And We’ll Reveal Your Actual Type
- Changing your birth control won’t change how much you love your partner, global study finds
- Americans Are Turning to AI for Credit Help—But Is It Working?
- Why cooler PCE inflation data won’t fix today’s mortgage rates
- REITs in Retirement: Steady Income or Too Much Risk?
- New York sues Kalshi, says prediction market is running ‘illegal gambling operation’
- UK millionaires fall to 442,000, lowest since 2008
